Toronto Dominion Bank Acquires 3,315 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Toronto Dominion Bank increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 27.3% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 15,466 shares of the biopharmaceutical company's stock after purchasing an additional 3,315 shares during the period. Toronto Dominion Bank's holdings in Alnylam Pharmaceuticals were worth $4,254,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $26,000. Huntington National Bank increased its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC grew its holdings in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 153 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.1 %

NASDAQ ALNY traded up $0.18 during trading hours on Friday, reaching $245.44. The company's stock had a trading volume of 592,047 shares, compared to its average volume of 860,965. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The stock has a market cap of $31.66 billion, a P/E ratio of -93.68 and a beta of 0.32. The firm has a fifty day simple moving average of $267.01 and a 200-day simple moving average of $249.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business's revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.15 EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares of the company's stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares in the company, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,122 shares of company stock worth $2,540,455 over the last ninety days. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALNY. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Cantor Fitzgerald restated a "neutral" rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.